Published 1 day ago • loading... • Updated 1 day ago

Teva Reports Final Analysis of Migraine Prevention Trial of Ajovy

Summary by Clinical Trials Arena

Teva Pharmaceutical has reported the final analysis of the PEARL Phase IV migraine prevention trial of Ajovy (fremanezumab).The post Teva reports final analysis of migraine prevention trial of Ajovy appeared first on Clinical Trials Arena.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

neurologylive.com

Phase 4 PEARL Study Confirms Long-Term Effectiveness of Fremanezumab in Preventing Chronic, Episodic Migraine

Fremanezumab shows significant long-term effectiveness in reducing migraine frequency and severity, enhancing patient outcomes in chronic and episodic cases.

1 day ago

Read Full Article